CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Label-free chimeric antigen receptor T-cell expression analysis using neural networks and statistical distribution modeling.
Label-free chimeric antigen receptor T-cell expression analysis using neural networks and statistical distribution modeling.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T(CAR-T)细胞疗法已成为血液系统恶性肿瘤的有前景治疗方法。准确监测 CAR 表达水平对于优化疗效和保障患者安全至关重要。传统评估依赖基于抗体的流式细胞术(FCM),过程耗时且可能改变细胞特性。本研究提出一种新型无标记方法,利用明场显微成像和深度学习预测 CAR 表达率。该方法将卷积神经网络与分类得分分布分析相结合,并采用高斯拟合估算 CAR 表达率。在 4 位供者样本中,其预测值与标准 FCM 测量结果的误差均在 5% 以内,最大预测误差从 13% 降至 4.4%。这是首次成功实现对 T 细胞 CAR 表达率的无标记预测,为 CAR-T 细胞实时监测和制备提供了实用方案。该方法仅依赖标准明场显微镜,可直接用于制备和研究场景。
Chimeric antigen receptor T (CAR-T)-cell therapy has emerged as a promising treatment for hematologic malignancies. Accurate monitoring of CAR expression levels is essential for optimizing therapeutic efficacy and ensuring patient safety. Conventional assessments rely on antibody-based flow cytometry (FCM)-a labor-intensive process that may alter cellular properties.
This study introduces a novel label-free method for predicting CAR expression rates using bright-field microscopy and deep learning. The proposed approach integrates convolutional neural networks with classification score distribution analysis by employing Gaussian fitting to estimate CAR expression rates. It achieved a prediction accuracy within 5 % of standard FCM measurements across four donors, reducing the maximum prediction error from 13 % to 4. 4 %.
This study represents the first successful label-free prediction of CAR expression rates in T cells, offering a practical solution for real-time monitoring and manufacturing of CAR-T cells. This method is readily applicable to manufacturing and research settings, as it relies solely on standard bright-field microscopy.
MEMBER ACCOUNT
登录成功会直接打开下一页。